Kevin Bottomley

Partner, Europe

Kevin is a partner at Results, and he joined the firm in 2012 in response to client demand for a dedicated healthcare practice. Kevin has over 30 years’ experience working in the healthcare sector, principally with pharmaceutical, biotechnology, business consultancy and M&A transaction advisory companies. He has been involved in the successful transaction of many businesses, acting as advisor to investors, major pharmaceutical, biotechnology as well as service companies to the life sciences industries.

During his career Kevin has held senior positions in pharmaceutical research, alliance management, business development and transactions. He has worked at Hoechst (Sanofi), Quintiles (IQVIA), Roche Pharmaceuticals, Inpharmatica and PharmaVentures.

Outside of work, Kevin is kept busy walking his two Shetland sheep dogs round the Chiltern Hills.

Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less. ― Marie Curie

Latest Insights

19th January 2022

Predictions for Life Sciences Industries for 2022, and no ‘San Francisco’ This Year!

The Covid 19 pandemic continues to have a major impact on the healthcare industry, both positive if you are close to the discovery and provision of treatments for this infection and negative if you are selling certain other drugs, such as antibiotics or providing care services, which have been negatively impacted by this pandemic. However, […]

19th August 2020

Rising to the challenge: the response of UK biopharmaceuticals to the COVID-19 pandemic

Hindsight is a gift that every politician desires and with it, perhaps we would have been better prepared for the COVID-19 pandemic, acted more quickly, with greater certainty and ultimately more effectively. Given that this is a new disease, which was first characterised at the end of 2019, the UK biopharma industry (and the global […]

23rd April 2020

Will the spin-off of Sanofi pharmaceutical chemistry manufacturing happen now?

Earlier in 2020 in a pre-COVID-19 world, Sanofi announced its intention to spin off a significant part of their chemistry manufacturing capability with Sanofi sites in Brindisi, Italy; Frankfurt, Germany; Haverhill, England; St. Aubin les Elbeuf, France; Upjest, Hungary; and Vertolaye, France, forming a new company separated from Sanofi (but with Sanofi aspiring to own […]

14th April 2020

Life sciences supply chain resilience: now and post Covid-19

Without a doubt, life sciences supply chain resilience will be markedly different post Covid-19. There will be a massive restructuring generally of supply chains for strategic products such as drugs, diagnostics, personal safety equipment, food, chemicals etc., driven by national governmental actions in response to the Covid-19 pandemic. On the positive side, researchers have come […]

Corporate News
3rd April 2020

Exceptional circumstances call for exceptional support

During these uncertain times, we are all working hard to equip our businesses to survive and thrive in a very challenging economic environment. In our experience, the response window is short and learning from the successes and failures of others, vital. Each member of our senior team has spent between 15 and 40 years working […]

22nd November 2019

Outsourced Pharmaceutical Manufacturing 2020

Outsourced Pharmaceutical Manufacturing 2020: Current Trends & Future Prospects In our latest analysis of the commercial and clinical contract manufacturing market, we predict the sector to grow at a CAGR of 6.8% to c. $117bn in 2023, with certain sub-sectors such as viral vector and pre-filled syringe manufacturing achieving significant double-digit growth. The Contract Development […]

20th September 2018

Biosimilars: prospects and challenges

The adoption of biosimilars varies from country to country, which is invariably linked to regulatory and market access issues. These differences have made it difficult for many investors to make decisions about entering the market with confidence. The situation should improve as more biosimilars reach the market, their benefits become embedded in healthcare systems, and regulatory pathways […]